Logo image of TIC

ACUREN CORPORATION (TIC) Stock Fundamental Analysis

USA - NYSE:TIC - US00510N1028 - Common Stock

14.4 USD
+0.95 (+7.06%)
Last: 9/19/2025, 8:04:01 PM
14.22 USD
-0.18 (-1.25%)
After Hours: 9/19/2025, 8:04:01 PM
Fundamental Rating

2

Overall TIC gets a fundamental rating of 2 out of 10. We evaluated TIC against 82 industry peers in the Professional Services industry. While TIC has a great health rating, there are worries on its profitability. TIC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

TIC had positive earnings in the past year.
TIC had a positive operating cash flow in the past year.
TIC Yearly Net Income VS EBIT VS OCF VS FCFTIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 0 5M 10M

1.2 Ratios

TIC has a Return On Assets (2.48%) which is comparable to the rest of the industry.
TIC has a Return On Equity (2.48%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA 2.48%
ROE 2.48%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TIC Yearly ROA, ROE, ROICTIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 0 0.5 1 1.5 2

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TIC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TIC Yearly Profit, Operating, Gross MarginsTIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, TIC has less shares outstanding
There is no outstanding debt for TIC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TIC Yearly Shares OutstandingTIC Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 10M 20M 30M 40M 50M
TIC Yearly Total Debt VS Total AssetsTIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

TIC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
TIC Yearly LT Debt VS Equity VS FCFTIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 886.16 indicates that TIC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 886.16, TIC belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
TIC has a Quick Ratio of 886.16. This indicates that TIC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TIC (886.16) is better than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 886.16
Quick Ratio 886.16
TIC Yearly Current Assets VS Current LiabilitesTIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 100M 200M 300M 400M 500M

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TIC will show a small growth in Earnings Per Share. The EPS will grow by 1.74% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2Y-48.27%
EPS Next 3Y-6.65%
EPS Next 5Y1.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TIC Yearly Revenue VS EstimatesTIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 500M 1B 1.5B 2B
TIC Yearly EPS VS EstimatesTIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 0.1 0.2

0

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 57.60, the valuation of TIC can be described as expensive.
69.51% of the companies in the same industry are cheaper than TIC, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.38, TIC is valued quite expensively.
Industry RankSector Rank
PE 57.6
Fwd PE N/A
TIC Price Earnings VS Forward Price EarningsTIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

67.07% of the companies in the same industry are cheaper than TIC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 356.69
EV/EBITDA N/A
TIC Per share dataTIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

A cheap valuation may be justified as TIC's earnings are expected to decrease with -6.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.27%
EPS Next 3Y-6.65%

0

5. Dividend

5.1 Amount

TIC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ACUREN CORPORATION

NYSE:TIC (9/19/2025, 8:04:01 PM)

After market: 14.22 -0.18 (-1.25%)

14.4

+0.95 (+7.06%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryProfessional Services
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)N/A N/A
Inst Owners73.6%
Inst Owner ChangeN/A
Ins Owners16.72%
Ins Owner Change33.45%
Market Cap2.89B
Analysts80
Price Target14.79 (2.71%)
Short Float %4.47%
Short Ratio3.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.82%
PT rev (3m)4.82%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 57.6
Fwd PE N/A
P/S N/A
P/FCF 356.69
P/OCF 356.69
P/B 5.22
P/tB 5.22
EV/EBITDA N/A
EPS(TTM)0.25
EY1.74%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY0.28%
OCF(TTM)0.04
OCFY0.28%
SpSN/A
BVpS2.76
TBVpS2.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.48%
ROE 2.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset TurnoverN/A
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 58.95%
Current Ratio 886.16
Quick Ratio 886.16
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2Y-48.27%
EPS Next 3Y-6.65%
EPS Next 5Y1.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y443.42%
EBIT Next 5Y259.06%
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A